The gut microbiome may play a role in response to anti-PD-1 immune checkpoint inhibitor therapy, new research suggests.
The study in patients with metastatic melanoma found that a patient’s ability to respond to the treatment hinged on the presence of a diverse microbiome as well as specific bacterial species.
The findings were released February 21 ahead of a presentation later this week at the inaugural American Society of Clinical Oncology (ASCO)/Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Symposium in Orlando, Florida.
The study was supported by the Moon Shot program at MD Anderson Cancer Center, the Melanoma Research Alliance and the Parker Institute for Cancer Immunotherapy. Several authors disclosed financial relationships with various pharmaceutical companies.